Zobrazeno 1 - 10
of 13
pro vyhledávání: '"J. T. Fine"'
MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists
Publikováno v:
Drug Safety
Introduction Within the field of Pharmacovigilance, the most common approaches for assessing causality between a report of a drug and a corresponding adverse event are clinical judgment, probabilistic methods and algorithms. Although multiple methods
Autor:
Cartic Ramakrishnan, Sujan Perera, Meenakshi Nagarajan, J. T. Fine, Shawman Meireis, Shaun Comfort, Zoe Hudson, Darren Dorrell
Publikováno v:
Drug Safety
Introduction There is increasing interest in social digital media (SDM) as a data source for pharmacovigilance activities; however, SDM is considered a low information content data source for safety data. Given that pharmacovigilance itself operates
Autor:
James Ward, J. T. Fine, Ivan J. Suñer, Chantal M. Dolan, Tsontcho Ianchulev, Neil M. Bressler, Paul P. Lee, Rohit Varma, Tom S. Chang
Publikováno v:
Ophthalmology. 120(1)
To determine the impact of ranibizumab on driving status, driving ability perception, and having 20/40 vision or better in patients with choroidal neovascularization resulting from age-related macular degeneration (AMD).Phase III, multicenter, random
Publikováno v:
Archives of ophthalmology (Chicago, Ill. : 1960). 127(1)
Objective To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT). Design Multicenter, double-masked, phase 3 trial (ANCHOR). Participan
Autor:
Timothy D. Henry, Amy Chen Rundle, James T. Willerson, Frank J. Giordano, Brian H. Annex, Daniel S. Berman, Edward R. McCluskey, John J. Lopez, George R. McKendall, Alex Bajamonde, J. T. Fine, Prediman K. Shah, C. Michael Gibson, Raymond L. Benza, Michael Azrin
Publikováno v:
Circulation. 107(10)
Background— Recombinant human vascular endothelial growth factor protein (rhVEGF) stimulates angiogenesis in animal models and was well tolerated in Phase I clinical trials. VIVA (Vascular endothelial growth factor in Ischemia for Vascular Angiogen
Autor:
Quan V. Doan, Elizabeth Selvin, Neil M. Bressler, Chantal M. Dolan, Mark D. Danese, J. T. Fine, Shoshana Colman, Julie K. Bower, Adam Turpcu, Michelle Gleeson, Rohit Varma
Publikováno v:
JAMA Ophthalmology. 132:1334
Importance Diabetic macular edema (DME) is a leading cause of vision loss in persons with diabetes mellitus. Although there are national estimates for the prevalence of diabetic retinopathy and its risk factors among persons with diabetes, to our kno
Autor:
J. T. Fine, Shoshana Colman, Julie K. Bower, Neil M. Bressler, Quan V. Doan, Michelle Gleeson, Adam Turpcu, Mark D. Danese, Elizabeth Selvin, Chantal M. Dolan, Rohit Varma
Publikováno v:
JAMA Ophthalmology. 132:168
Importance Thickening of the center of the retina, diabetic macular edema (DME), is the most common cause of visual loss due to diabetes mellitus. Treatment of DME has improved dramatically, and the prompt diagnosis of DME and referral of these patie
Publikováno v:
The Journal of urology. 157(5)
We assessed health related quality of life in patients with advanced renal cell carcinoma treated with nephrectomy and tumor infiltrating lymphocyte therapy in combination with interleukin-2.A total of 20 patients with advanced renal cell carcinoma w
Autor:
Anne M. Rentz, Peggy R. Orr, Neil M. Bressler, Dennis A. Revicki, J. T. Fine, Chantal M. Dolan, Shoshana Colman, Mary Kay Margolis
Publikováno v:
Investigative Opthalmology & Visual Science. 53:7950
Autor:
Neil M. Bressler, Mary Kay Margolis, Peggy R. Orr, Chantal M. Dolan, Anne M. Rentz, Dennis A. Revicki, J. T. Fine, Shoshana Colman
Publikováno v:
Investigative Opthalmology & Visual Science. 52:3354
PURPOSE Patient-reported measures of visual function are increasingly incorporated into clinical trials of new treatments for age-related macular degeneration (AMD). Limited information is available regarding the associations between distance visual